288 studies found for:    "Alkylating Agents" | updated in the last 30 days
Show Display Options
Rank Status Study
1 Recruiting Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma
Condition: Newly Diagnosed Ewing Sarcoma
Interventions: Drug: Cyclophosphamide;   Device: Doxorubicin;   Drug: Vincristine;   Device: Ifosfamide;   Drug: Etoposide;   Procedure: Surgery;   Radiation: Radiation Therapy*;   Drug: Temozolomide;   Drug: Irinotecan
2 Recruiting Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)
Conditions: Lupus Erythematosus;   Graft-versus-host Disease
Interventions: Drug: Cyclophosphamide;   Drug: Sodium-2-mercapto ethane sulphonate;   Drug: Fludarabine monophosphate;   Drug: Tacrolimus;   Drug: Mofetil;   Drug: Rabbit antithymocyte globulin
3 Not yet recruiting Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Bendamustine + Rituximab
4 Recruiting Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy
Condition: Hematologic Malignancies
Intervention: Drug: Cyclophosphamide
5 Recruiting Ph 3 Trial of Blinatumomab vs Investigator's Choice of Chemotherapy in Patients With Relapsed or Refractory ALL
Condition: Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Interventions: Drug: Blinatumomab;   Drug: Standard of Care Chemotherapy
6 Not yet recruiting SAR650984 Combined to CyBorD in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant
Condition: Haematological Malignancy
Interventions: Drug: SAR650984;   Drug: bortezomib;   Drug: cyclophosphamide;   Drug: dexamethasone
7 Recruiting Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children
Conditions: Relapsed Solid Tumors;   Refractory Solid Tumors;   Leukemias
Interventions: Drug: Carfilzomib;   Drug: Cyclophosphamide;   Drug: Etoposide
8 Completed Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells
Conditions: Stem Cell Transplantation;   Bone Marrow Transplantation;   Peripheral Blood Stem Cell Transplantation;   Allogeneic Transplantation,;   Genetic Diseases;   Thalassemia;   Pediatrics;   Diamond-Blackfan Anemia;   Combined Immune Deficiency;   Wiskott-Aldrich Syndrome;   Chronic Granulomatous Disease;   X-linked Lymphoproliferative Disease;   Metabolic Diseases
Interventions: Drug: Cyclophosphamide Dose Level 1;   Drug: Cyclophosphamide Dose Level 2;   Drug: Cyclophosphamide Dose Level 3;   Drug: Cyclophosphamide Dose Level 4
9 Not yet recruiting Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
Conditions: Cutaneous T-cell Lymphoma;   T-Prolymphocytic Leukemia;   T-Large Granulocytic Leukemia;   T-Lymphoblastic Leukemia/Lymphoma;   Peripheral T-Cell Lymphoma
Interventions: Drug: Romidepsin;   Drug: Busulfan;   Drug: Fludarabine;   Procedure: Stem Cell Transplant
10 Not yet recruiting Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
Conditions: Glioblastoma Multiforme;   Astrocytoma, Grade IV
Interventions: Biological: Personalized peptide vaccine;   Drug: Poly ICLC;   Drug: GM-CSF;   Drug: Temozolomide
11 Active, not recruiting Trabectedin and Irinotecan for Refractory Pediatric Sarcomas
Conditions: Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Rhabdomyosarcoma
Intervention: Drug: Combined chemotherapy with trabectedin followed by irinotecan
12 Not yet recruiting Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies
Conditions: Non Hodgkin Lymphoma;   Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Multiple Myeloma
Intervention: Drug: Thiotepa
13 Not yet recruiting A Phase II Study of NovoTTF-100A Alone and With Temozolomide in Patients With Low-Grade Gliomas
Condition: Glioma
Interventions: Device: NovoTTF-100A;   Drug: Temozolomide
14 Withdrawn Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma
Conditions: Basal Cell Carcinoma of the Skin;   Eccrine Carcinoma of the Skin;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Melanoma;   Recurrent Skin Cancer;   Squamous Cell Carcinoma of the Skin;   Stage III Adult Soft Tissue Sarcoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Melanoma
Interventions: Drug: isolated limb perfusion;   Drug: melphalan;   Procedure: quality-of-life assessment
15 Not yet recruiting Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Busulfan;   Drug: Palifermin;   Drug: Panobinostat;   Drug: Gemcitabine;   Drug: Melphalan;   Drug: Dexamethasone acetate;   Drug: Caphosol;   Drug: Glutamine;   Drug: Pyridoxine;   Procedure: Stem Cell Transplant
16 Recruiting Neoadjuvant FDC With Melatonin or Metformin for Locally Advanced Breast Cancer.
Condition: Breast Cancer
Interventions: Drug: metformin;   Drug: Fluoruracil;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: melatonin
17 Not yet recruiting Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma
Conditions: Plasma Cell Leukemia;   Recurrent Plasma Cell Myeloma
Interventions: Biological: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Methotrexate;   Biological: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Drug: Tacrolimus
18 Not yet recruiting Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide
Condition: Breast Cancer
Interventions: Drug: Docetaxel;   Drug: Cyclophosphamide;   Other: Function Assessment of Cancer Therapy (FACT) Surveys
19 Not yet recruiting Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Primary Malignant Brain Tumors
Conditions: Glioblastoma Multiforme;   Glioma;   Gliosarcoma;   Malignant Brain Tumor;   Ependymoma;   Medulloblastoma
Interventions: Drug: Indoximod;   Drug: Temozolomide;   Radiation: Conformal Radiation
20 Recruiting Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients
Condition: HIV
Intervention: Genetic: SB-728mR-HSPC Infusion 3 days following busulfan conditioning

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years